Shionogi Completes $2.5B Acquisition of Radicava Rights

Shionogi has completed its acquisition of global rights to Radicava (edaravone) and Radicava ORS, two edaravone formulations approved to treat amyotrophic lateral sclerosis (ALS), from Tanabe Pharma. Shionogi acquired the rights as a wholly owned subsidiary for about $2.5 billion, plus potential royalties tied to future sales.

Shionogi said it will ensure continuity of care and supply for ALS patients using Radicava. The transfer covers major countries and regions, with remaining regions to be transferred sequentially. The acquisition also brings more than 100 team members from Tanabe Pharma America into Shionogi, along with Radicava programs and platforms.